The overall goal of the Program Project structure is to provide an environment that fosters detailed, multi- disciplinary characterizafion of the development of virus-specific and cross-reactive (XR) CDS+ T cells, using the Epstein Barr virus (EBV) model of human infecfion. Each project in this Program Project is interdependent with regard to expertise, resources, and experimental design and requires access to high- quality clinical specimens and similar technologies. Core A will provide the necessary scientific leadership (including Internal and External Advisory Boards) and administrative and fiscal support to facilitate these mulfi-disciplinary, collaborafive studies. These multidisciplinary studies will result in large and diverse data sets;experts in bioinformafics and biostafistics will not only assist in the development of an integrated database but will also help develop and apply appropriate analytical approaches. In the absence of a suitable animal model, human studies are essenfial. The University of Massachusetts Amherst (UMA) Health Services Acute Infecfious Mononucleosis (AIM) Clinic provides essential clinical samples and constitutes one of a very few longitudinal AIM cohorts in the worid. Over the years, we have altered clinical visit and sample collection schedules to address evolving scienfific quesfions. While the AIM Clinic remains the main source of our clinical samples, the newly created UMA EBV Serosurveillance Cohort will allow us to obtain updated estimates of EBV seroposifivity and seroconversion in college students. Work conducted over the past funding period has identified high frequencies of influenza and EBV XR CD8+ T cells in the circulafion of a small group of individuals who remain EBV uninfected into their third decade of life and beyond. This has led to a novel hypothesis (i.e., that high frequencies of these cross-reactive CDS+ T cells might protect against EBV infecfion) and organizafion of a new cohort (EBV Seronegative;EBV-SN) that will be recruited to address this new hypothesis in the next funding period.
The proposed studies will invesfigate factors that control the evolution of human anfiviral CD8+ T cell responses from the acute effector phase into long-term memory and how anfigen-specific or cross-reactive CD8+ T cells contribute to viral control or disease. We hope that they will inform the development of antiviral vaccines that afford long-term protecfion against infection or disease, while minimizing potential adverse effects. By providing scientific leadership, administrative and fiscal support, an integrated database/data analysis, and unique clinical samples. Core A is essenfial to the Program Project's overall success.
Showing the most recent 10 out of 38 publications